Spotlight
Topic
Brand Insights
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Earnings: Tough Times Ahead
Article
Pharmaceutical Executive
Pharmaceutical ExecutivePharmaceutical Executive-03-01-2001
Volume 0
Issue 0
Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.
Articles in this issue
Research: New Horizons
The Challenge of Prescription Drug Pricing
Earnings: Tough Times Ahead
Antigenics: Quest for a Cure
Outbreak: Anthrax Alarm
Patents: China on the Genome Map
Privacy, Pediatrics, and Policy
Lilly's International Family
Update: Punishment and Reprieve
Biotech: Down for the Count
Shortage: Vaccine Worries
Access: Success Story
Gateway to Japan
Surrounded
Related Videos
Related Content
Fierce Females in the Life Science Space
March 29th 2024Podcast
In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
